EVA Basel
VC Fund
Basel, Switzerland
EVA Basel is a VC fund in Basel focused on Biotechnology and Medical Device. EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries EVA Basel invests in
Stages EVA Basel invests in
Countries EVA Basel invests in
Round sizes
Round size
- Seed
- $1.9M–$3.1M
Investment Focus
Industry
- Biotechnology 2 (50%)
- Medical Device 2 (50%)
- Medical 1 (25%)
- Robotics 1 (25%)
- Navigation 1 (25%)
Stage
- Seed 2 (50%)
- Series A 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner. | $3.1M / Seed / May 14, 2018 | ||
| Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner. | $3.1M / Seed / May 12, 2016 | ||
| Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $2.3M / Series A / Jul 22, 2015 | ||
| AOT AG is a privately owned Swiss Robotic Surgery company, which spun out of the University Hospital and the University Basel (Switzerland) in 2011 and was first funded in 2012. The company is dedicated to the development, manufacturing and sales of medical devices for osteotomy pursuing the vision of contact-free bone surgery using laser,robotics and navigation systems to re-invent bone surgery (osteotomy). | $1.9M / Seed / Jan 25, 2012 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does EVA Basel invest in?
EVA Basel invests primarily in Biotechnology, Medical Device and Medical startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is EVA Basel's check size?
EVA Basel typically joins rounds of $1.9M–$3.1M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds EVA Basel participates in.
When did EVA Basel last invest?
The most recent investment recorded for EVA Basel closed in May 2018. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
